- Valuation Model
- Expert Interviews
- Founders, funding
How does the prevalence of stem cell treatments in Europe compare to that of the United States and the rest of the world?
Kathryn Cross
Co-founder & CEO at Anja Health
The US is definitely a bit behind. About 2% of parents in the US today bank their stem cells, whereas in certain areas of China, it's as high as 10%, and in Singapore it’s reported to be around 30%.
Generally, the US is not known for having the most stellar healthcare system, and there's a lot of opportunity for preventative care to be put at the forefront of parenting healthcare, maternal healthcare, infant healthcare and prenatal healthcare. The US is definitely able to be a part of something really contemporary, but it hasn't become particularly widespread since a lot of people don't have access to proper healthcare.
We do work with physicians that tell their patients about us, and recommend us, but it's not particularly widespread. Especially older OBs are just not kept up-to-date with the research that's ongoing around cord blood stem cells. There's a real opportunity for us to be able to help educate them and things like that.
For instance, we went to this OB-GYN conference a couple weeks ago and spoke to hundreds of OB-GYNs about cord blood, cord tissue and placenta stem cells—a lot of them just weren't briefed on it in med school, and barely heard about it throughout their residency. Maybe they’d come across it once or twice but they just didn't have enough exposure.